Summit Partners Public Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Summit Partners Public Asset Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-42,214	Closed	-$6.73M	–	120
2022 Q4	$6.73M	Sell	42,214 -87,826	-68%	-$12.9M	0.43%	60
2022 Q3	$17.3M	Buy	130,040 +13,524	+12%	+$2.06M	0.89%	39
2022 Q2	$18.2M	Buy	+116,516	New	+$17.9M	0.82%	39
2018 Q4	–	Sell	-139,893	Closed	-$23.5M	–	78
2018 Q3	$23.5M	Buy	139,893 +49,893	+55%	+$8.58M	1.59%	18
2018 Q2	$15.5M	Sell	90,000 -20,000	-18%	-$3.27M	1.72%	16
2018 Q1	$16.6M	Buy	+110,000	New	+$16.1M	2.35%	13
2017 Q3	–	Sell	-65,000	Closed	-$10.1M	–	99
2017 Q2	$10.1M	Buy	+65,000	New	+$9.94M	1.38%	27

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Summit Partners Public Asset Management's JAZZ Position: Q1 2023 in Review

Summit Partners Public Asset Management sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2023, closing a stake of 42,214 shares — an estimated $6.73M sold.

Summit Partners Public Asset Management first reported a position in JAZZ in Q2 2017 and held it in 7 quarters. The position peaked at $23.5M in Q3 2018. 471 funds tracked by Wall St. Rank hold JAZZ as of Q1 2023.

Summit Partners Public Asset Management reported no remaining Jazz Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Summit Partners Public Asset Management sold 42,214 Jazz Pharmaceuticals shares in Q1 2023, an estimated $6.73M.
Summit Partners Public Asset Management first reported a position in Jazz Pharmaceuticals in Q2 2017 and held it in 7 quarters.
Summit Partners Public Asset Management's Jazz Pharmaceuticals position peaked at $23.5M in Q3 2018.
471 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2023.

Based on Summit Partners Public Asset Management's 13F filing for Q1 2023, filed 15 May 2023.